Precision BioSciences, Inc.

226 articles about Precision BioSciences, Inc.

• Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

  9/12/2023

  Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments.

• Precision BioSciences to Attend and Present at Upcoming September 2023 Investor Conferences

  9/6/2023

  Precision BioSciences, Inc., a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, announced that members of management will participate in the following investor conferences in the month of September.

• Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

  8/31/2023

  Precision BioSciences, Inc., a gene editing company developing ARCUS®-based in vivo gene editing therapies, announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.

• Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

  8/15/2023

  Precision BioSciences, Inc. (Nasdaq: DTIL) today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.

• Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/4/2023

  Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

• Precision BioSciences to Report Second Quarter Results on August 4, 2023

  8/1/2023

  Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.

• Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

  7/27/2023

  Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day.

• Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

  6/22/2023

  Precision BioSciences Announces Oral Presentation of Positive ARCUS ® Gene Editing Data at International Liver Congress 2023.

• Precision BioSciences to Present at Upcoming June Investor Conferences

  6/5/2023

  Precision BioSciences, Inc. today announced that members of management will participate in the following investor conferences in June 2023.

• Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

  5/31/2023

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced program updates across its allogeneic CAR T pipeline.

• Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023

  5/25/2023

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on May 31, 2023 at 8:30 AM ET.

• Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day

  5/24/2023

  Precision BioSciences, Inc. today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023.

• Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

  5/19/2023

  Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting.

• Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

  5/12/2023

  Precision BioSciences, Inc. announced that its late-breaking abstract presenting preclinical in vivo gene editing data for its PBGENE-DMD program, being developed for the potential treatment of Duchenne muscular dystrophy, is available through the American Society of Gene & Cell Therapy 26th Annual Meeting.

• Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

  5/9/2023

  Precision BioSciences, Inc. today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

• Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 08, 2023

  5/8/2023

  Precision BioSciences, Inc. announced that, on April 27, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.

• Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

  5/2/2023

  Precision BioSciences, Inc. today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.

• Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

  4/20/2023

  Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023.

• Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

  4/18/2023

  Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting.

• Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

  4/13/2023

  Precision BioSciences, Inc. today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/606,856, titled “Engineered meganucleases specific for recognition sequences in the PCSK9 gene.”